Skip to content

Rationale and design of a prospective, single-center, cohort study to prediction accuracy of ARDS by using a association of biomarkers and lung injury prediction score

Rationale and design of a prospective, single-center, cohort study to prediction accuracy of ARDS by using a association of biomarkers and lung injury prediction score

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040276
Enrollment
Unknown
Registered
2020-11-27
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute respiratory disease syndrome

Interventions

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Screen the patients admitted to the ICU every day to see if they have at least one major risk factor for ARDS, including: bacteremia, sepsis/septic shock, sepsis, shock, severe pancreatitis, pneumonia, lung Contusion, inhalation of foreign bodies in the lung, multiple blood transfusions, multiple fractures, high-risk trauma or high-risk surgery, and staying in ICU for more than 72 hours.

Exclusion criteria

Exclusion criteria: For patients with risk factors for ARDS, check whether they meet the exclusion criteria. Exclusion conditions include: patients <18 years old, HIV infection, cytotoxic drug treatment, neutropenia (except secondary to sepsis), other known immunodeficiencies (leukemia, general immunodeficiency syndrome, etc.), Solid organ or bone marrow transplantation, chronic lung disease (except COPD and asthma), vasculitis, granulocyte, granulocyte-macrophage colony stimulating factor treatment, decided to give up monitoring. Patients who meet any one of the exclusion conditions will be excluded from the study cohort.

Design outcomes

Primary

MeasureTime frame
interleukin-8;human neutrophil elastase;receptor for advanced glycation end products;peptidase inhibitor 3;angiopoeitin-2;

Countries

China

Contacts

Public ContactZhu Xi

Peking University Third Hospital

xizhuccm@sina.com+86 13601186413

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026